Jacob Thaysen

Jacob Thaysen became CEO of Illumina in late 2023, stepping into a company that had just gone through one of the most dramatic corporate governance battles in biotech history. The contested acquisition of cancer-screening company GRAIL led to activist investor Carl Icahn winning board seats, the departure of former CEO Francis deSouza, and a mandate to divest GRAIL — leaving Illumina refocused on its core sequencing franchise. Illumina commands over 80% of the global next-generation DNA sequencing market, making it the foundational infrastructure provider for genomics. Its NovaSeq and NextSeq platforms are installed in virtually every major research institution, clinical laboratory, and pharmaceutical company worldwide. Thaysen's mission is to accelerate adoption of the NovaSeq X series (which dramatically reduces per-genome sequencing costs), expand clinical and direct-to-consumer applications, and explore multi-omics — integrating genomic, proteomic, and transcriptomic data. His execution on the NovaSeq X ramp, pricing strategies for consumables, and ability to re-establish investor confidence after the GRAIL turmoil are the critical drivers of Illumina's stock price. The long-term secular trend toward genomic medicine and population-scale sequencing programs provides a powerful demand backdrop, but near-term capital discipline and margin recovery are the market's primary focus areas.